Study for multiple myeloma resistance and relapse changes
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma or your multiple myeloma has come back
- Your diagnosis must match the international criteria doctors use for multiple myeloma
- You must be able and willing to sign consent and allow use of your biological samples (biocollection)
- You must be covered by a social security program or similar healthcare coverage
- You cannot be a minor, and you cannot be under major guardianship/curatorship
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.